F18-Choline, a Novel PET Tracer for Parathyroid Adenoma?

Elske Quak, Stéphanie Lheureux, Yves Reznik, Stéphane Bardet, Nicolas Aide

The Journal of Clinical Endocrinology & Metabolism · 2013 · 79 citations · 4 references

Concepts

Abstract

A 71-year-old man was referred for F18-fluorocholine (F18-choline) positron emission tomography (PET)/ computed tomography (CT) because of suspected prostate cancer recurrence after radical prostatectomy. The F18choline PET/CT was negative for recurrent prostate cancer. However, intense choline uptake was seen in a small lesion adjacent to the right lower pole of the thyroid (Figure 1). As we found out, the patient was analyzed for a primary hyperparathyroidism at the same time. Laboratory values were: calcium, 2.84 mmol/L (normal 2.15– 2.55); PTH, 91.8 pg/L (normal 80); and vitamin D, 31.4 ng/mL (normal 30–74). Thus, we evoked the hypothesis of a right-sided parathyroid adenoma (PTA). A few days later, parathyroid scintigraphy with Tc99m-sestamibi (MIBI) and ultrasonography were performed, and both were concordant with the PET/CT findings. The PTA was subsequently removed by minimally invasive surgery. Histology confirmed the diagnosis. After surgery, calcium levels normalized. To our knowledge, this is the first report of PTA localization with F18-choline PET/CT. We found one report of a C11-choline-positive PTA (1). The potential advantages of a PET tracer instead of MIBI for PTA localization are better spatial resolution allowing for smaller lesion detection and a shorter study protocol due to the rapid biokinetics of choline (2, 3). F18-choline is preferable over C11choline due to its much better availability worldwide and its favorable imaging characteristics. In conclusion, F18-choline PET/CT seems a promising new tool in PTA imaging. A prospective validation focusing on its usefulness as a second-line tracer in the one-third of MIBI negative patients (4) is required.

References

4